In NSCLC, RET fusions are mutually exclusive with other driver mutations, such as ALK or ROS1 rearrangements or EGFR or KRAS mutations, once again suggesting common signaling mechanisms [13,116]. The gene discussed is RET; the disease is non-small cell lung carcinoma.